Abstract
Plasma cell dyscrasias are a group of related disorders that have in common the clonal proliferation of plasma cells with resultant production of a monoclonal immunoglobulin that can be detected on serum protein electrophoresis (M-spike). This term incorporates the Plasma Cell Neoplasms along with other related disorders that are not considered malignant. Comprehensive genomic studies have greatly advanced our understanding of the genetic complexity of these diseases in recent years, however they continue to be considered incurable with a highly heterogeneous phenotype. It is clear that a deeper level of knowledge of the biological events underlying the development of these diseases is needed to identify new targets and generate effective novel therapies. MicroRNAs (miRNAs), which are single strand, 20- nucleotide, non-coding RNAs, are key regulators of gene expression and have been reported to exert transcriptional control in multiple myeloma and other plasma cell dyscrasias. miRNAs are now recognized to play a role in many key areas such as cellular proliferation, differentiation, apoptosis and stress response. Substantial advances have been made in recent years in terms of our understanding of the biological role of miRNAs in this complex and diverse set of disorders, leading to the new information, which is of diagnostic and prognostic relevance.
Keywords: MGUS, miRNA, multiple myeloma, plasma cell, regulation, waldenstrom’s macroglobulinemia.
MicroRNA
Title:The Role of miRNAs in Plasma Cell Dyscrasias
Volume: 2 Issue: 3
Author(s): Siobhan Glavey, Salomon Manier, Antonio Sacco, Giuseppe Rossi, Irene M. Ghobrial and Aldo M. Roccaro
Affiliation:
Keywords: MGUS, miRNA, multiple myeloma, plasma cell, regulation, waldenstrom’s macroglobulinemia.
Abstract: Plasma cell dyscrasias are a group of related disorders that have in common the clonal proliferation of plasma cells with resultant production of a monoclonal immunoglobulin that can be detected on serum protein electrophoresis (M-spike). This term incorporates the Plasma Cell Neoplasms along with other related disorders that are not considered malignant. Comprehensive genomic studies have greatly advanced our understanding of the genetic complexity of these diseases in recent years, however they continue to be considered incurable with a highly heterogeneous phenotype. It is clear that a deeper level of knowledge of the biological events underlying the development of these diseases is needed to identify new targets and generate effective novel therapies. MicroRNAs (miRNAs), which are single strand, 20- nucleotide, non-coding RNAs, are key regulators of gene expression and have been reported to exert transcriptional control in multiple myeloma and other plasma cell dyscrasias. miRNAs are now recognized to play a role in many key areas such as cellular proliferation, differentiation, apoptosis and stress response. Substantial advances have been made in recent years in terms of our understanding of the biological role of miRNAs in this complex and diverse set of disorders, leading to the new information, which is of diagnostic and prognostic relevance.
Export Options
About this article
Cite this article as:
Glavey Siobhan, Manier Salomon, Sacco Antonio, Rossi Giuseppe, Ghobrial M. Irene and Roccaro M. Aldo, The Role of miRNAs in Plasma Cell Dyscrasias, MicroRNA 2013; 2 (3) . https://dx.doi.org/10.2174/2211536602666131126002144
DOI https://dx.doi.org/10.2174/2211536602666131126002144 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Recent Patents on Anti-Cancer Drug Discovery Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Effects of Tyrosine Kinase Inhibitors on Growth and Bone Metabolism in Children with Haematologic Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Current Gene Therapy Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery
Current Topics in Medicinal Chemistry Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Xenograft models of primary acute myeloid leukemia for the development of imaging strategies and evaluation of novel targeted therapies.
Current Pharmaceutical Biotechnology Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets An Overview of Data Mining Algorithms in Drug Induced Toxicity Prediction
Mini-Reviews in Medicinal Chemistry Targeting Heat Shock Protein 90 for Malaria
Mini-Reviews in Medicinal Chemistry Antimicrobial Action of Chelating Agents: Repercussions on the Microorganism Development, Virulence and Pathogenesis
Current Medicinal Chemistry Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Chemogenomics of Sensitivity and Resistance to Anticancer Drugs
Current Pharmacogenomics The Role of TRP Channels in Allergic Inflammation and its Clinical Relevance
Current Medicinal Chemistry Recent Anticancer Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents